Markets:

Overview

News

Currencies

International

Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

33.24 -0.82 (-2.41%)

Streaming Delayed Price Updated: 11:32 AM EDT, Jun 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged ↗

April 02, 2025

Edgewise Therapeutics stock dropped, as Cytokinetics shares got a big boost early Wednesday.

Via Investor's Business Daily

Topics Bankruptcy

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 02, 2025

Via Benzinga

Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday ↗

March 27, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

March 21, 2025

Via Benzinga

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

March 11, 2025

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025

March 04, 2025

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

March 03, 2025

From Edgewise Therapeutics, Inc.

Via Business Wire

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development

January 22, 2025

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

January 13, 2025

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

January 07, 2025

From Edgewise Therapeutics

Via Business Wire

Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday ↗

December 16, 2024

Via Benzinga

Dow Eyes Worst Losing Streak Since 2018 ↗

December 16, 2024

The Nasdaq Composite is up triple digits midday, hitting fresh record highs as it looks to build off a fourth-straight weekly win.

Via Talk Markets

Topics Stocks Stocks / Equities

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease ↗

December 16, 2024

Edgewise Therapeutics reports promising Phase 2 results for sevasemten, showing reduced muscle damage and well-tolerated safety in Becker muscular dystrophy.

Via Benzinga

Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket ↗

December 16, 2024

Via Benzinga

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

December 16, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research

December 05, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

November 26, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 07, 2024

From Edgewise Therapeutics

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 16, 2024

Via Benzinga

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

October 01, 2024

From Edgewise Therapeutics

Via Business Wire

MarketBeat Week in Review – 9/23 - 9/27

September 28, 2024

Stocks had a mostly bullish week as stimulus efforts in the U.S. and China enhanced risk-on sentiment, but next week's jobs report could spark a larger rally

Via MarketBeat

Topics Economy

Analysts Think There's Still Time to Get in on Edgewise, Up 332%

September 25, 2024

Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run?

Via MarketBeat

Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗

September 22, 2024

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week.

Via Benzinga

Topics Economy

Crude Oil Gains Over 1%; Mobileye Global Shares Jump ↗

September 19, 2024

Via Benzinga

Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

September 19, 2024

Edgewise Therapeutics is rocketing higher on positive results for its HCM combating treatment and short-covering. Expect volatility in the weeks ahead.

Via MarketBeat

Why Edgewise Therapeutics Stock Is Up 50% on Thursday ↗

September 19, 2024

One of the biopharma company's heart drugs performs as well as initially hoped.

Via The Motley Fool

Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings ↗

September 19, 2024

Via Benzinga

Topics Stocks

Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment ↗

September 19, 2024

Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic cardiomyopathy, showing the drug was well tolerated with reductions in LVOT...

Via Benzinga

Darden Restaurants Posts Q1 Results, Joins Tesla, Nvidia, XPeng And Other Big Stocks Moving Higher On Thursday ↗

September 19, 2024

Via Benzinga

Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip ↗

September 19, 2024

Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.